Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib
Oncotarget · 2025
DOI: 10.18632/oncotarget.28730 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncotarget, 2025. Verfasst von Jinah Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Vermont Medical Center, Burlington, VT 05401, USA. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Vermont Medical Center, Burlington, VT 05401, USA.
- Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- The Queen's Medical Center, Honolulu, HI 96813, USA.
- NIH, Bethesda, MD 20894, USA.
- John H. Stroger, Jr. Hospital of Cook County, Chicago, IL 60612, USA.
Zitieren
APA
Kim, J., Chung, L. I., Choi, H., Choi, Y., Chuchuca, M. J. A., Oh, Y., & Chae, Y. K. (2025). Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib. Oncotarget. https://doi.org/10.18632/oncotarget.28730
Vancouver
Kim J, Chung LI, Choi H, Choi Y, Chuchuca MJA, Oh Y, et al. Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib. Oncotarget. 2025. doi:10.18632/oncotarget.28730
BibTeX
@article{Kim2025,
author = {Kim, Jinah and Chung, Liam Il-Young and Choi, Horyun and Choi, Yoonhee and Chuchuca, Maria Jose Aguilera and Oh, Youjin and Chae, Young Kwang},
title = {Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib},
journal = {Oncotarget},
year = {2025},
doi = {10.18632/oncotarget.28730}
}
EUVIMED